-
XPENG Launches Two New Models in UK; Pony.ai Robotaxi Enters Pilot
-
Pilot-Founded Solara Global Jet Offers Charter, Leases and Air Cargo Nationwide and Overseas
-
How to Turn Your Garage into Usable Living Space
-
Three Inaugural CombatX Champions Crowned at BRAVE CF Road to BRAVE Event in Hungary
-
French Economy Shrinks 0.1% as Consumer Confidence Slumps
-
China's Factory Activity Contracts as Export Orders Weaken
-
Wall Street Ends Turbulent Week Higher Despite Inflation and AI Jitters
-
US Retail Sales and Fed Minutes Set Up a Critical Test for Consumers
-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
-
Luxury Skincare Brand Faces Backlash Over Futurist Manifesto Aesthetic
-
Asian Markets Slide as AI Concerns Hit Chip Stocks
-
Brazil Faces Debt and Inflation Test as Lula Prepares Fourth Term
-
Canada Signals Openness to Chinese Automakers if US Trade Talks Fail
-
Canada Expands Asian Trade Push as US Negotiations Resume
-
US Mortgage Rate Falls for Fourth Week but Remains Above 7%
-
US Jobless Claims Rise to 200,000 but Layoffs Remain Historically Low
-
Italy Raises 2026 Growth View but Warns Energy Will Keep Inflation High
-
Godzilla Minus Zero Review: Takashi Yamazaki’s Anti-Nuclear Allegory
-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
DA Demands No-Work-No-Pay for Striking Municipal Workers in Coalition Talks
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
-
India's Retail Inflation Reaches 6.09% as Food Prices Accelerate
-
India's Wholesale Inflation Jumps to 12.29% as Fuel Costs Surge
-
Malta Emerges as Premier Low-Season Destination for UK Travelers
-
China's October Activity Data Reveal a Weak Start to the Fourth Quarter
-
Japan's Economy Edges Into Contraction as Costly Oil Weighs on Demand
-
Philippines Urges ASEAN and China to Accelerate South China Sea Code of Conduct
-
UK Home Asking Prices Drop £6,745 in November Amid High Mortgage Rates
Onco-Innovations Appoints Dr. Dennis Hall to Scientific & Clinical Advisory Board
VANCOUVER, BC / ACCESS Newswire / July 21, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(Frankfurt:W1H)(WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce the appointment of Dr. Dennis Hall, Professor of Chemistry at the University of Alberta, to its Scientific and Clinical Advisory Board.
Dr. Hall is internationally recognized for his pioneering work in organoboron chemistry, catalysis, and medicinal chemistry, including the development of DNA repair inhibitors. He currently holds the Tier 1 Canada Research Chair in Boron Chemistry for Catalysis and Drug Discovery, and leads a multidisciplinary research team dedicated to the development of novel synthetic and biological applications of boron-containing compounds.[1]
With over 175 peer-reviewed publications, two books, and 15 book chapters, Dr. Hall's contributions span catalysis, heterocyclic chemistry, and medicinal chemistry. He has mentored more than 75 graduate students and postdoctoral fellows, and his work has been widely cited with over 18,000 citations and an h-index of 70.[2] Among his numerous accolades are the Arthur C. Cope Scholar Award (2024) from the American Chemical Society[3], the R. U. Lemieux Award (2021) from the Canadian Society for Chemistry[4], and a Killam Research Fellowship (2019-2021). He was elected a Fellow of the Royal Society of Canada in 2017. [5]
As part of his role, Dr. Hall will serve on the Scientific and Clinical Advisory Board and provide strategic advice to the Company on its Research and Development agenda, including clinical discovery, synthesis and manufacturing, pre-clinical testing, and clinical translation plans associated with Polynucleotide Kinase 3 Phosphatase (PNKP) Inhibitor Technology NP/A83. He will also collaborate with the Company's scientific and clinical leadership, as well as external partners, to advance oncology-focused innovations.
"Dr. Hall's appointment marks a significant step in bridging advanced synthetic chemistry with translational oncology. His expertise in boron-based drug discovery is uniquely aligned with our mission to develop precision therapies, and we look forward to leveraging his insight as we push our PNKP Inhibitor Technology toward the clinic," stated Thomas O'Shaughnessy, CEO of Onco-Innovations.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
[email protected]
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's technologies, the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize its technologies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
J.Gomez--AT